BMG Pharma and HTL Biotechnology sign an agreement for the production of the functional ingredient underlying the patented Hyaluromimethic® technology

15 Sep, 2022 | News & Media

The latest news

Mastrodonato (BMG Pharma): without innovation you cannot be successful

Mastrodonato (BMG Pharma): without innovation you cannot be successful

Are you interested in knowing the point of view of our founder and CEO Marco Mastrodonato about how to do pharmaceutical entrepreneurship?

Read his interview on Caltalks:
“Thinking outside the box”, innovation as secret of the success.
BMG Pharma performs the concept of innovation in the biotech sector, relying on chemical structure modification of biotechnological origin for the development of new chemical entities and improving their functions and efficacy, differentiating itself from all competitors on the market. “Our strategy,” Mastrodonato continues, “is to develop biotechnology products covering both aesthetic dermatology and osteoarthritis.”
In BMG Pharma we find not limits, but solutions, the company wants to be present in the market bringing new products based on science and aligning itself with an evolving context, trying to deliver in the hands of the physician something truly innovative, interactive, and effective to propose to the patient.

To read the whole interview, click here: https://www.caltalks.com/2023/11/mastrodonato-bmg-pharma-senza.html

BMG Pharma launches new “Hyaluromimethic” technology

BMG Pharma launches new “Hyaluromimethic” technology

Since 2011, BMG Pharma has been an Italian excellence serving the biotechnology sector, which is bringing great innovations to the biopolymers sector.
Follow the Sole24Ore interview with our CEO Marco Mastrodonato regarding the new Hyaluromimethic ® technological platform and the projects in development.

BMG Pharma
We Make it Happen

Torviscosa - BMG Pharma reaches patent record

Torviscosa - BMG Pharma reaches patent record

A business plan focused on commercial expansion, research and development. In two years, the company created 4 new patents and registered 36 innovative products, as well as launching 37 on an international scenario.

BMG Pharma and Massimo Doris join the company

BMG Pharma and Massimo Doris join the company

Massimo Doris, CEO of Banca Mediolanum buys 2% of the share package, creating a corporate form with the company specializing in the production of new biomaterials derived from hyaluronic acid.